Loading clinical trials...

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

NCT07107178•Biotroy Therapeutics

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy .
•2. Adequate organ and hematologic function.
•3. At least 1 extracranial measurable lesion.
•4. An ECOG activity status score of 0-1.
•5. A life expectancy of ≥ 3 months.
•6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.
•7. Good compliance and willingness to follow up.

Exclusion Criteria

•1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days.
•2. A history of active autoimmune disease within the past 2 years.
•3. A history of clinically significant cardiovascular disease, severe cardiac rhythm/conduction abnormalities or LVEF\<50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea.
•4. A severe acute or chronic infection when enrollment.
•5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .
•6. Unresolved \> grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.
•7. Clinically active CNS metastases or meningeal metastases.
•8. A history of other type of malignancies.
•9. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.
•10. Poor compliance.
+3 more criteria

Key Dates

Start Date

August 8, 2025

Primary Completion Date

May 1, 2027

Completion Date

August 1, 2027

Last Updated

August 6, 2025

Enrollment

ESTIMATED participants

Conditions

Advanced MelanomaAdvanced Solid Tumor

Interventions

BT02

DRUG

Contacts

Clinical development director

CONTACT

+86-18602185973 clin.oper@biotroy.cn

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Study of PYX-201 in Advanced Solid Tumors

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study of ASP1002 in Adults for Treatment of Solid Tumors